

**I. ELECTION**

Applicants elect without traverse Group I (claims 1-13 and 16-20), as drawn to a method of controlled ovarian hyperstimulation in a mammalian female, for further prosecution on the merits. Applicants further elect the following species without traverse:

- a. From the FSH substances, Applicants elect recombinant FSH and amounts thereof
- b. From the GnRH antagonists, Applicants elect ganirelix and amounts thereof
- c. From the LH substances, Applicants elect recombinant LH and amounts thereof
- d. From the ML substances, Applicants elect urinary hCG and amounts thereof

Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications. Claims 1-20 are readable on the elected species. Applicants respectfully submit that the generic claims are allowable and that all species may be properly rejoined and such rejoinder is requested.

U.S. Appln. No. 10/517,028  
Filed: June 15, 2005


Attorney Docket No: 05558.0025.PCUS00

**CONCLUSION**

The Examiner is hereby respectfully invited to contact the undersigned attorney at the number listed below with any questions, comments or suggestions relating to this application.

Respectfully submitted,

HOWREY LLP

By:   
David W. Clough, Ph.D.  
Registration No: 36,107  
Customer No. 22930

Dated: October 24, 2007

HOWREY LLP  
321 N. Clark Street, Suite 3400  
Chicago, IL 60610  
(312) 595-1239 (main)  
(312) 595-1408 (direct)  
(312) 595-2250 (fax)

## **Appendix A**

- Group I. Claims 1-13 and 16-20, drawn to a method of controlled ovarian hyperstimulation in a mammalian female; and
- Group II. Claims 14-15, drawn to a pharmaceutical kit.